Recent progress of the research on peroxisome proliferator-activated receptor α-selective ligands

Hiroyuki Miyachi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor a (PPARalpha) as a regulator of lipid and lipoprotein homeostasis, and the rapid development of parallel high-throughput screening assays to evaluate the activity toward other PPAR subtypes (PPARdelta and PPARgamma), have provided an opportunity to develop novel PPARalpha-selective, PPARalpha/gamma dual and PPAR pan agonists for the treatment of various metabolic diseases. This review focuses on the molecular pharmacology of PPARalpha, and summarizes recent literature and patent applications disclosing medicinal chemistry strategies to identify new PPARalpha-selective agonists. The species selectivity of some classes of PPARalpha-selective agonists in response to in vitro PPARalpha transactivation activity is also reported.

Original languageEnglish
Pages (from-to)746-754
Number of pages9
JournalIDrugs
Volume7
Issue number8
Publication statusPublished - Aug 2004
Externally publishedYes

Fingerprint

PPAR alpha
Peroxisome Proliferator-Activated Receptors
Ligands
Research
PPAR gamma
PPAR delta
High-Throughput Screening Assays
Pharmaceutical Chemistry
Metabolic Diseases
Cytoplasmic and Nuclear Receptors
Transcriptional Activation
Lipoproteins
Homeostasis
Pharmacology
Lipids

Keywords

  • Metabolic disorders
  • Peroxisome proliferatoractivated receptorα
  • Phenoxyacetic acid
  • Species selectivity

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Recent progress of the research on peroxisome proliferator-activated receptor α-selective ligands. / Miyachi, Hiroyuki.

In: IDrugs, Vol. 7, No. 8, 08.2004, p. 746-754.

Research output: Contribution to journalArticle

@article{2bce298d2ffa43a796d8845a3b5ffc0c,
title = "Recent progress of the research on peroxisome proliferator-activated receptor α-selective ligands",
abstract = "The understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor a (PPARalpha) as a regulator of lipid and lipoprotein homeostasis, and the rapid development of parallel high-throughput screening assays to evaluate the activity toward other PPAR subtypes (PPARdelta and PPARgamma), have provided an opportunity to develop novel PPARalpha-selective, PPARalpha/gamma dual and PPAR pan agonists for the treatment of various metabolic diseases. This review focuses on the molecular pharmacology of PPARalpha, and summarizes recent literature and patent applications disclosing medicinal chemistry strategies to identify new PPARalpha-selective agonists. The species selectivity of some classes of PPARalpha-selective agonists in response to in vitro PPARalpha transactivation activity is also reported.",
keywords = "Metabolic disorders, Peroxisome proliferatoractivated receptorα, Phenoxyacetic acid, Species selectivity",
author = "Hiroyuki Miyachi",
year = "2004",
month = "8",
language = "English",
volume = "7",
pages = "746--754",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "8",

}

TY - JOUR

T1 - Recent progress of the research on peroxisome proliferator-activated receptor α-selective ligands

AU - Miyachi, Hiroyuki

PY - 2004/8

Y1 - 2004/8

N2 - The understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor a (PPARalpha) as a regulator of lipid and lipoprotein homeostasis, and the rapid development of parallel high-throughput screening assays to evaluate the activity toward other PPAR subtypes (PPARdelta and PPARgamma), have provided an opportunity to develop novel PPARalpha-selective, PPARalpha/gamma dual and PPAR pan agonists for the treatment of various metabolic diseases. This review focuses on the molecular pharmacology of PPARalpha, and summarizes recent literature and patent applications disclosing medicinal chemistry strategies to identify new PPARalpha-selective agonists. The species selectivity of some classes of PPARalpha-selective agonists in response to in vitro PPARalpha transactivation activity is also reported.

AB - The understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor a (PPARalpha) as a regulator of lipid and lipoprotein homeostasis, and the rapid development of parallel high-throughput screening assays to evaluate the activity toward other PPAR subtypes (PPARdelta and PPARgamma), have provided an opportunity to develop novel PPARalpha-selective, PPARalpha/gamma dual and PPAR pan agonists for the treatment of various metabolic diseases. This review focuses on the molecular pharmacology of PPARalpha, and summarizes recent literature and patent applications disclosing medicinal chemistry strategies to identify new PPARalpha-selective agonists. The species selectivity of some classes of PPARalpha-selective agonists in response to in vitro PPARalpha transactivation activity is also reported.

KW - Metabolic disorders

KW - Peroxisome proliferatoractivated receptorα

KW - Phenoxyacetic acid

KW - Species selectivity

UR - http://www.scopus.com/inward/record.url?scp=16544373479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544373479&partnerID=8YFLogxK

M3 - Article

C2 - 15334308

AN - SCOPUS:16544373479

VL - 7

SP - 746

EP - 754

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 8

ER -